Myocarditis as systemic disease: New perspectives on pathogenesis

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 12, 1997, Pages 997-1003

  Carthy, Christopher M ^a   Yang, Decheng ^a   Anderson, Daniel R ^a   Wilson, Janet E ^a   McManus, Bruce M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cardiomyopathy; Coxsackievirus; Spleen; Translation

Indexed keywords

CONFERENCE PAPER; COXSACKIE VIRUS B; GENE AMPLIFICATION; HEART DILATATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; LYMPH NODE; MYOCARDITIS; SPLEEN; TISSUE INJURY; VIREMIA; VIRUS REPLICATION;

EID: 0030777643     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb02739.x     Document Type: Conference Paper

References (75)

1. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO. The natural history of idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1981; 47: 525-31.
2. Dec GW, Palacios IF, Fallen JT, Aretz HT. Active myocarditis in the spectrum of acute dilated cardiomyopathies. N. Engl. J. Med. 1985; 312: 885-90.
3. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy. Analysis of 152 necropsy patients. Am. J. Cardiol. 1987; 60: 1340-55.
4. Aretz HT, Billingham ME, Edwards WD et al. Myocarditis: A histopathologic definition and classification. Am. J. Cardiovasc. Pathol. 1987; 1: 3-14.
5. McManus BM, Wood SM. Inflammatory manifestations of toxic and allergic injury to heart and blood vessels. In: Bishop SP, Kerns WD (eds). Cardiovascular Toxicology. Elsevier, New York. 1997 (in press).
6. McManus BM, Gauntt CJ, Cassling RS. Immunopathologic basis of myocardial injury. In: Waller BF (ed.). Contemporary Issues in Cardiovascular Pathology. FA Davis Co, Philadelphia. 1987; 163-84.
7. Woodruff JF. Viral myocarditis. A review. Am. J. Pathol. 1980; 101: 425-84.
8. Clements GB. Characteristics of viruses inducing cardiac disease. In: Banatvala JE (ed.). Viral Infections of the Heart. Edward Arnold, London. 1993; 1-22.
9. O'Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Inst. J. 1987; 14: 268-75.
10. Grist NR, Reid D. Epidemiology of viral infections of the heart. In: Banatvala JE (ed.). Viral Infections of the Heart. Edward Arnold, London. 1993: 23-31.
11. Figulla HR, Kandolf R, McManus B (eds). Idiopathic Dilated Cardiomyopathy: Cellular and Molecular Mechanisms, Clinical Consequences. Springer Verlag, Berlin, Heidelberg. 1993.
12. Martino TA, Liu P, Petric M, Sole MJ. Enteroviral myocarditis and dilated cardiomyopathy: A review of clinical and experimental studies. In: Rotbart HA (ed.). Human Enterovirus Infections. ASM Press, Washington. 1995; 291-351.
13. Archard LC, Bowles NE, Olsen EGJ, Richardson PJ. Detection of persistent Coxsackie B virus RNA in dilated cardiomyopathy and myocarditis. Eur. Heart J. 1987; 8: 437-40.
14. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of Coxsackie-B virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986; i: 1120-3.
15. Bowles NE, Rose ML, Taylor P et al. End-stage dilated cardiomyopathy: Persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation 1989; 80: 1128-36.
16. Kandolf R, Klingel K, Mertsching H et al. Molecular studies on enteroviral heart disease: Patterns of acute and persistent infections. Eur. Heart J. 1991; 12(Suppl. D): 49-55.
17. Tracy SM, Chapman NM, McManus BM et al. A molecular and seralogic evaluation of enteroviral involvement in human myocarditis, J. Mol. Cell. Cardiol. 1990; 22: 403-14.
18. McManus BM, Kandolf R. Evolving concepts of cause, consequence, and control in myocarditis. Curr. Opin. Cardiol. 1991; 6: 418-27.
19. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-3.
20. Tomko RP, Xu R, Philipson L. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl Acad. Sci. USA 1997; 94: 3352-6.
21. Bergelson JM, Mohanly JG, Crowell RL, St John NF, Lublin DM, Finberg RW. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J. Virol. 1995; 69: 1903-6.
22. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J. Virol. 1995; 69: 3873-7.
23. de Verdugo UR, Selinka HC, Huber M et al. Characterization of a 100-kilodalton binding protein for the six serotypes of coxsackie B viruses. J. Virol. 1995; 69: 6751-7.
24. Huber SA, Lodge PA. Coxsackievirus B-3 myocarditis in BALB/c mice. Evidence for autoimmunity to myocyte antigens. Am. J. Pathol. 1984; 116: 21-9.
25. Rose NR, Hill SL. The pathogenesis of postinfectious myocarditis. Clin. Immunol. Immunopathol. 1996; 80: S92-9.
26. Neumann DA, Rose NR, Ansari AA, Herskowitz A. Induction of multiple heart autoantibodies in mice with Coxsackievirus B3- and cardiac myosin-induced autoimmune myocarditis. J. Immunol. 1994; 152: 343-50.
27. Gauntt CJ, Arizpe HM, Higdon AL et al. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. J. Immunol. 1995; 154: 2983-95.
28. McManus BM, Chow LH, Wilson JE et al. Direct myocardial injury by enterovirus: A central role in the evolution of murine myocarditis. Clin. Immunol. Immunopathol. 1993; 68: 159-69.
29. Klingel K, Hohenadl C, Canu A et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: Quantitative analysis of virus replication, tissue damage, and inflammation. Proc. Natl Acad. Sci. USA 1992; 89: 314-18.
30. Kandolf R. Molecular biology of viral heart disease. Herz 1993; 18: 238-44.
31. Kandolf R, Ameis D, Kirschner P, Canu A, Hofschneider PH. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc. Natl Acad. Sci. USA 1987; 84: 6272-6.
32. Klingel K, Stephan S, Sauter M et al. Pathogenesis of murine enterovirus myocarditis: Virus dissemination and immune cell targets. J. Virol. 1996; 70: 8888-95.
33. Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency. Lab. Invest. 1992; 66: 24-31.
34. Huber SA. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab. Invest. 1997; 76: 691-701.
35. Savill J. Apoptosis in resolution of inflammation. J. Leukoc. Biol. 1997; 61: 375-80.
36. Lowenstein CJ, Hill SL, Lafond-Walker A et al. Nitric oxide inhibits viral replication in murine myocarditis. J. Clin. Invest. 1996; 97: 1837-43.
37. Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S. Cytokine and murine Coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage. Circulation 1994; 89: 2836-42.
38. Ilback NG, Wesslen L, Pauksen K, Stalhandske T, Friman G, Fohlman J. Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease. Scand. J. Infect. Dis. Suppl. 1993; 88: 117-23.
39. Hiraoka Y, Kishimoto C, Takada H et al. Nitric oxide and murine coxsackievirus B3 myocarditis: Aggravation of myocarditis by inhibition of nitric oxide synthase. J. Am. Coll. Cardiol. 1996; 28: 1610-15.
40. Fohlman J, Pauksen K, Hyypia T et al. Antiviral treatment with WIN 54954 reduces mortality in murine Coxsackievirus B3 myocarditis. Circulation 1996; 94: 2254-9.
41. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine Coxsackievirus B3 model. Antiviral and anti-inflammatory effects. Circulation 1995; 92: 1604-11.
42. Liu P, Penninger J, Aitken K, Sole M, Mak T. The role of transgenic knockout models in defining the pathogenesis of viral heart disease. Eur. Heart J. 1995; 16 (Suppl. O): 25-7.
43. Kishimoto C, Thorp KA, Abelmann WH. Immunosuppression with high doses of cyclophosphamide reduces the seventy of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis. Circulation 1990; 82: 982-9.
44. Mason JW, O'Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N. Engl. J. Med. 1995; 333: 269-75.
45. Anderson DR, Wilson JE, Carthy CM, Yang D, Kandolf R, McManus BM. Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J. Virol. 1996; 70: 4632-45.
46. Vuorinen T, Vainionpaa R, Vanharanta R, Hyypia T. Susceptibility of human bone marrow cells and hematopoietic cell lines to coxsackievirus B3 infection. J. Virol. 1996; 70: 9018-23.
47. Vuorinen T, Vainionpaa R, Kettinen H, Hyypia T. Coxsackievirus B3 infection in human leukocytes and lymphoid cell lines. Blood 1994; 84: 823-9.
48. Anderson GW, Rowland RR, Palmer GA, Even C, Plagemann GW. Lactate dehydrogenase-elevating virus replication persists in liver, spleen, lymph node, and testis tissues and results in accumulation of viral RNA in germinal centers, concomitant with polyclonal activation of B cells. J. Virol. 1995; 69: 5177-85.
49. Chakrabarti L, Isola P, Cumont MC, Claessens-Maire MA, Montagnier L, Hurtrel B. Early stages of simian immunodeficiency virus infection in lymph nodes. Am. J. Pathol 1994; 144: 1226-37.
50. Beebe AM, Dua N, Faith TG, Moore PF, Pedersen NC, Dundekar S. Primary stage of feline immunodeficiency virus infection: Viral dissemination and cellular targets. J. Virol. 1994; 68: 3080-91.
51. Jacoby RO, Johnson EA, Ball-Goodrich L, Smith AL, McKisik MD. Characterization of mouse parvovirus infection by in situ hybridization. J. Virol. 1995; 69: 3915-19.
52. Stoddart CA, Cardin RD, Boname JM, Manning WC, Abenes GB, Mocarski ES. Peripheral blood mononuclear phagocytes mediate dissemination of murine cytomegalovirus. J. Virol. 1994; 68: 6243-53.
53. Matteucci D, Toniolo A, Conaldi PG, Basolo F, Gori Z, Bendinelli M. Systemic lymphoid atrophy in coxsackievirus B3-infected mice: Effects of virus and immunopotentiating agents. J. Infect. Dis. 1985; 151: 1100-8.
54. Bendinelli M, Matteucci D, Toniolo A, Patane AM, Pistillo MP. Impairment of immunocompetent mouse spleen cell functions by infection with coxsackievirus B3. J. Infect. Dis. 1982; 146: 797-805.
55. Huber SA, Mortensen A, Moulton G. Modulation of cytokine expression by CD4+ T cells during coxsackievirus B3 infections of BALB/c mice initiated by cells expressing the gamma delta + T-cell receptor. J. Virol. 1996; 70: 3039-44.
56. Tishon A, Manchester M, Scheiflinger F, Oldstone MB. A model of measles virus-induced immunosuppression: Enhanced susceptibility of neonatal human PBLs. Nature Med. 1996; 2: 1250-4.
57. Karp CL, Wysocka M, Wahl LM et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science 1996; 273: 228-31.
58. McChesney MB, Oldstone MB. Virus-induced immunosuppression: Infections with measles virus and human immunodeficiency virus. Adv. Immunol. 1989; 45: 335-80.
59. Borrow P, Evans CF, Oldstone MB. Virus-induced immunosuppression: Immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J. Virol. 1995; 69: 1059-70.
60. Battegay M, Moskophidis D, Waldner H et al. Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. J. Immunol. 1993; 151: 5408-15.
61. Huber SA, Job LP, Woodruff JF. Sex-related differences in the pattern of coxsackievirus B-3-induced immune spleen cell cytotoxicity against virus-infected myofibers. Inject. Immun. 1981; 32: 68-73.
62. Tracy S, Tu Z, Chapman N, Hufnagel G. Genetics of coxsackievirus B3 cardiovirulence. Eur. Heart J. 1995; 16 (Suppl. O): 15-17.
63. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDN A of the Woodruff variant of coxsackievirus B3. J. Virol. 1996; 70: 7811-18.
64. Tu ZG, Chapman NM, Hufnagel G et al. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5′ nontranslated region. J. Virol. 1995; 69: 4607-18.
65. Lee YF, Nomoto A, Detjen BM, Wimmer E. The genome linked protein of picornaviruses: A protein covalently linked to poliovirus genome RNA. Proc. Natl Acad. Sci. USA 1977; 74: 59-63.
66. Minor PD. The molecular biology of poliovirus. J. Gen. Virol. 1992; 73: 3065-77.
67. Hershey JWB. Translation control in mammalian cells. Annu. Rev. Biochem. 1992; 60: 717-55.
68. Jang SK, Krausslich HG, Nicklin MJH, Duke GM, Palmenberg AC, Wimmer E. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 1988; 62: 2636-43.
69. Davies MV, Kaufman RJ. The sequence context of the initiation codon in the encephalomyocarditis virus leader modulates efficiency of internal translation initiation. J. Virol. 1992; 66: 1924-32.
70. Yang DC, Wilson JE, Anderson DR et al. In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5′ untranslated region of coxsackievirus B3: Potential targets tor antiviral action of antisense oligomers. Virology 1997; 228: 63-73.
71. Belsham GJ, Sonenberg N. RNA-protein interactions in regulation of picornavirus RNA translation. Microbiol. Rev. 1996; 60: 499-511.
72. Gutierrezescolano L, Delangel RM. Nuclear proteins bind to poliovirus 5′ untranslated region. Arch. Med. Res. 1996; 27: 413-19.
73. Borman AM, Kirchweger R, Ziegler E, Rhoads RE, Skern T, Kean KM. EIF4G and its proteolytic cleavage products: Effect on initiation of protein synthesis from capped, uncapped, and ires-containing mRNAs. RNA 1997; 3: 186-96.
74. Gan WN, Rhoads RE. Internal initiation of translation directed by the 5′-untranslated region of the mRNA for EIF4G, a factor involved in the picornavirus-induced switch from cap-dependent to internal initiation. J. Biol. Chem. 1996; 271: 623-6.
75. Huber M, Selinka HC, Kandolf R. Tyrosine phosphorylation events during coxsackievirus B3 replication. J. Virol. 1997; 71: 595-600.